Leaflet IPRAXA 250mcg / ml inhalation solution by nebulization


Indicated for: nasal congestion; rhinitis

Substance: ipratropium bromide (antimuscarinic bronchodilator)

ATC: R03BB01 (Respiratory system | Other drugs for obstructive airway diseases, inhalants | Anticholinergics)

Ipratropium bromide is a bronchodilator used for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma. It works by blocking muscarinic receptors, relaxing airway muscles, and improving breathing.

The medication is administered as an aerosol or nebulizer solution, as directed by a doctor. It is important to follow the recommended dose to avoid side effects.

Side effects may include dry mouth, cough, throat irritation, or dizziness. In rare cases, severe allergic reactions or breathing difficulties may occur.

Ipratropium bromide is not recommended for patients with hypersensitivity to this medication or other anticholinergics.

General data about IPRAXA 250mcg / ml

  • Substance: ipratropium bromide
  • Date of last drug list: 01-07-2013
  • Commercial code: W52855001
  • Concentration: 250mcg / ml
  • Pharmaceutical form: inhalation solution by nebulization
  • Quantity: 20
  • Product type: generic
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Concentrations available for ipratropium bromide

  • 20mcg/dose
  • 250mcg/2ml
  • 250mcg/ml
  • 500mcg/2ml

Combinations with other substances